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Mobile phone (cell phone) use is increasing extraor-
dinarily rapidly worldwide. There are now 4.6 billion
mobile phone subscribers worldwide.
1 In many low-
and middle-income countries use of cell phones has
made communications possible in vast areas lacking
cable connections. Increasingly, in high-income coun-
tries, cell phones have replaced ‘land lines’ for person-
al telecommunications. Users of mobile phones are
exposed to electromagnetic radiation, which has
long been hypothesized to have adverse health effects,
including increased risk of cancer.
2,3 Research on bio-
logical mechanisms of cellular and tissue injury by
electromagnetic radiation has been inconclusive, and
consequently epidemiological studies have been the
principal source of evidence on potential health risks
of mobile phone use. Brain tumours have been of
particular concern because the electromagnetic radi-
ation generated by mobile phones passes through the
brain when the phones are used without a hands-free
device. To date, findings of diverse studies on mobile
phone use and brain tumour risk have been reported
with mixed findings, but with no clear indication of
increased risk for cancer.
4,5 To provide needed evi-
dence on the potential risk of brain cancer associated
with mobile phone use, the International Agency for
Research on Cancer (IARC) initiated a multi-centre
case–control study, the INTERPHONE study, in
1998–99.
A much awaited report from this large international
study on mobile phone use and brain tumours is pub-
lished in this issue of the IJE.
6A number of previous
papers cited in the article reported only partial find-
ings from components of the multicentre study,
heightening expectations on what the full data set
would eventually show. The component studies were
relatively underpowered, but they exhibited a rather
consistent and baffling reduced risk among cell phone
users. We now have the complete results and the re-
searchers’ interpretation of them. The INTERPHONE
investigators conclude that ‘There were suggestions of
an increased risk of glioma, and much less of men-
ingioma, at the highest exposure levels, for ipsilateral
exposures and, for glioma, for tumours in the tem-
poral lobe. However, biases and errors limit the
strength of the conclusion we can draw from these
analyses and prevent a causal interpretation’.
6 This
statement, as with a similar one (‘...these biases
and errors prevent a causal interpretation of the re-
sults.’) at the end of the Appendix 2 of the article
6
added during the editorial process of revision, is both
elegant and oracular. Similar to any oracle it tolerates
diametrically opposite readings. If more weight is
given to the first sentence, a conclusion is reached
in favour of an increased risk, albeit not definitively
manifest yet, from intensive use of mobile phones.
Giving more weight to the second sentence leads to
the conclusion that there are enough sources of errors
in the study to dismiss the apparent elevated risks as
not real. With equal weight to the two sentences, any
conclusion hangs in the balance.
Is there any way out of this ambivalence?
INTERPHONE is the largest study yet carried out
and published on mobile phone use and cancer. It
includes 2409 cases of meningioma, 2708 cases of
glioma and two series of, respectively, 2662 and
2972 controls matched by age, sex and region of resi-
dence. With the coordination of IARC it has mobilized
investigators in multiple centres within 13 countries
‘...to determine whether mobile phone use increases
the risk of [brain] tumours and, specifically, whether
radiofrequency energy emitted by mobile phones is
tumorigenic’.
6
Certainly this is the question that scientists, people
and public health decision-makers have in mind, as
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not a cause of brain tumours. As defined by
Lowrance,
7 ‘a thing is safe if its risks are judged to
be acceptable’. This definition implies a need for
quantification of risk, the role of epidemiological re-
search and a judgement of its acceptability in individ-
ual and societal contexts. The risk of main interest is
lifelong use, possibly beginning in childhood—a pat-
tern of exposure that cannot yet be studied. The now
testable scientific question and that addressed by the
INTERPHONE study is whether mobile phones in-
crease the risk of brain tumours within the first
10–15 years of use, a question much less liable to
generate unwarranted expectations about the evi-
dence that the INTERPHONE study could actually de-
liver. In high-income countries, mobile phone use
began in the 1980s but was not widely prevalent
until the mid-1990s. The cancer cases in the study
were diagnosed between 2000 and 2004. As a conse-
quence, <5% (110/2409) of the meningioma cases
and <9% (252/2972) of the glioma cases occurred
410 years since start of mobile phone use. None of
the today’s established carcinogens, including to-
bacco, could have been firmly identified as increasing
risk in the first 10 years or so since first exposure.
Ionizing radiation is a recognized cause of brain tu-
mours but except for rare instances the radiation
induced cases occur on average after 10–20 years
since the time of first exposure. INTERPHONE
shares with all studies previously carried out on
mobile phones and cancer the inherent limitation
that it can investigate only a short period of observa-
tion since first exposure; the distribution of exposure
is brief and truncated leaving limited incubation time
for an exposure-related cancer to develop. Hence
observing no increase in risk would be reassuring
but only to a limited extent.
As a multi-centric study, INTERPHONE has, how-
ever, the potential advantage of incorporating simul-
taneous replication, if there is no methodological
heterogeneity across the centres. Consistency of re-
sults among centres, a key element for drawing
causal inferences, can be immediately examined,
rather than awaiting the accumulation of results
from successive and separate studies. Overall, a con-
sistent inter-country pattern of replicated reduced risk
for both meningioma and glioma is shown in Table 6
of Appendix 1 of the INTERPHONE article
6, whereas
Table 2 of the article shows an equally consistent pat-
tern of reduced risks for different metrics of exposure
(regular use vs never regular use, cumulative call
time, cumulative number of calls) with only three
odds ratios (ORs) out of 50 above 1. These results
are also in line with the detailed findings already pub-
lished in separate reports, involving nearly half of the
cancer cases, from some of the participating countries.
On the null hypothesis that there is no association
between mobile phone use and brain cancer, ORs
fluctuating randomly above and below 1 would be
expected, whereas the observed patterns of reduced
risks, on average of the order of 30%, would have a
tiny probability of occurring just by chance. Having
ruled out chance and the possibility of a protective
effect—absent any supporting biological evidence—
less plausible than the possibility of bias from a var-
iety of sources, bias stands as the most likely explan-
ation of the observed results. As already noted,
8 this
interpretation carries the uncomfortable consequence
that the interpretation of any result of the study
becomes problematic, unless the sources of bias are
identified and their consequences quantified.
The authors have carefully pursued bias as an ex-
planation of their findings via several routes.
Confronted with a participation rate appreciably
lower among controls (average for centres: 53%)
than among cases (averages of 78% for meningioma
and 64% for glioma), they asked a sample of partici-
pants (cases in 9 centres, controls in 11 centres) who
had refused the full interview to respond to a brief
questionnaire. Among both cases and controls,
non-participants reported a lower lifetime prevalence
of mobile phone use than participants. Since the par-
ticipation rate among controls was lower than among
cases, this pattern of response to the request for par-
ticipation introduces a lower frequency of regular
phone users among controls than among cases.
Extrapolating the findings from this sample to the
whole study population, the researchers estimated
6,9
that this selective non-participation bias may have led
to a reduction in the ORs for regular use of 5–15%,
potentially accounting for most of the bias observed
(Table 2 of the article
6) for meningioma [21%, 95%
confidence interval (CI) 9–32] and glioma (19%, 95%
CI 6–30). A substantiated downward and generalized
bias implies that any observed increase in risk would
be underestimated, independent of statistical signifi-
cance. If this bias extends to those with the highest
exposure, then an increased risk has been observed in
spite of this downward bias. In the top decile of cu-
mulative call time, the most comprehensive metric of
exposure, the observed and probably underestimated
ORs are 1.15 for meningioma and 1.40 for glioma
(Table 2 of the article
6). People in the top decile
used a mobile phone for a total of 51640h, still
not a very intensive use by today’s pattern: spread
over 10 years, the lower limit of this category is
about half an hour per day. Sensitivity analyses
(bottom part of Table 4 of Appendix 1 of the article
6)
show that the increased ORs are fairly consistent
among countries. They appear further increased
(Table 5: 1.45 for meningioma and 1.96 for glioma)
when the participant reported using the phone on the
same side of the tumour, yet the systematically higher
ORs for ipsilateral vs controlateral use, even at low
levels of exposure, points to reporting bias and casts
doubt on this latter result.
A second approach to bias investigation and correc-
tion is presented in Appendix 2 of the INTERPHONE
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6. To avoid the problem of a lower frequency of
regular users among controls (arising from non-parti-
cipation), ORs were calculated taking the lowest levels
of regular use as the reference category rather than
non-regular use. This approach has been often em-
ployed in occupational epidemiology when risk is
compared between people at various level of exposure
rather than between exposed and non-exposed sub-
jects, the latter being regarded as an entirely different
group. The table in Appendix 2 of the article
6 shows
that the ORs for meningioma are only slightly chan-
ged (cf. Table 2 of the article
6), whereas those for
gliomas are now mostly close to (and above) 1; the
OR for the top decile of cumulative call time has
increased from 1.40 to 1.82. The direction of these
corrections, the size of which may be questionable
(as discussed in Appendix 2 of the article
6) speaks
again in favour of a contribution of non-participation
bias to the observed low ORs. A further reason for the
downward bias may, however, lie in a different direc-
tion, briefly mentioned in Appendix 2 of the article
6.
Low risks have been a recurrent feature not only of
the INTERPHONE study, but also of other studies of
mobile phones and brain tumours, including a nation-
wide cohort study
10 in which non-participation was
not an issue. Major clinical manifestations of brain
tumours may not be long lasting but lesser symptoms,
including occasional seizures, may develop over sev-
eral years before diagnosis, as indicated by findings of
increased risk of brain tumours in people with a hos-
pital discharge diagnosis of epilepsy 58 years earlier,
the risk progressively increasing as the interval be-
tween epilepsy and tumour diagnosis becomes
shorter.
11 In addition, a nationwide cohort study
using the same database as the cohort brain cancer
investigation
12 found reduced hospitalization rates
among mobile phone users for a variety of central
nervous system diagnoses (Alzheimer’s disease, vas-
cular dementia, other dementia, Parkinson’s disease
and epilepsy) for time periods up to 10 years after
starting phone use. One explanation is that mobile
phone users may be a healthy group showing a
‘healthy user effect’ but a more likely one is that
people with prodromal manifestations of neurological
disease make less use of mobile phones. Along with
non-participation this selection bias may also contrib-
ute to the downward bias in the INTERPHONE study.
We commend the INTERPHONE investigators for a
rigorously implemented protocol and the careful ex-
ploration of bias. INTERPHONE clearly demonstrates
that epidemiological research has to give major em-
phasis to bias prevention and control. For the time
being, INTERPHONE’s findings, interpreted in the
context of prior studies, tells us that the question as
to whether mobile phone use increases risk for brain
cancers remains open. Given the relatively short time
of observation since first exposure and the acknowl-
edged biases we simply do not know the answer to
this question. Some may interpret the results
differently and most who have been awaiting the re-
sults of the INTERPHONE study will be disappointed
by its mixed findings. Those upholding a precaution-
ary approach to the extent and manner of use of
mobile phones may find some support in the elevated
risks noted in subjects with the highest exposures.
Not surprisingly, we end by calling for more re-
search, given the increasingly ubiquitous use of
mobile phones, rising use by children and the indica-
tion from some studies, including the INTERPHONE
study, that mobile phone use may increase risk for
brain tumours. One possibility to minimize selection
and information biases, proposed previously by
Rothman,
13 would track cohorts of mobile phone
users with exposures documented via company
records and outcomes ascertained through record
linkage with cancer registries. Large cohorts would
be required to investigate adult brain cancers that
have an incidence rate in the order of 10 per
100000 person-years but the advantage is that once
established a cohort can be repeatedly followed up in
time, updating exposure measurements in cases and a
random control sample. This type of investigation
overcomes the problem of case–control studies con-
ducted when not enough time has elapsed since
first exposure to make possible the emergence of
long latency adverse health effects. This approach
was blocked in the USA through litigation.
14
Another possibility would be periodic replication of
multi-centric case–control studies, comparable with
the INTERPHONE study in design, although the po-
tential for bias would likely remain.
Fortunately, high-quality cancer registries are in
place in many countries around the world and de-
scriptive patterns of brain tumour occurrence can be
monitored through careful and ongoing analyses to
detect changes suggestive of increased risk from
mobile phone use.
The tired refrain ‘more research is needed’ fully
applies in this instance: without more research the
public’s question about the acceptability of cancer
risk from mobile phones will remain unanswered.
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